The occurrence and potential role of mystical experiences in MDMA-assisted therapy for PTSD: A secondary analysis
Does the “mystical experience” associated with psychedelic therapy also explain therapeutic effects of MDMA-assisted therapy (MDMA-AT) for PTSD?
This is an interesting study because it addresses a specific mechanistic question: does the “mystical experience” associated with psychedelic therapy also explain therapeutic effects of MDMA-assisted therapy (MDMA-AT) for PTSD?
The study is a secondary analysis of data from two earlier Phase 2 randomized, active-placebo-controlled MDMA-AT trials. In this secondary analysis of MDMA-assisted therapy for PTSD the researchers found that mystical-type experiences can occur with MDMA, but overall mystical experience did not significantly mediate PTSD improvement. The Positive Mood component of the mystical-experience measure showed a significant mediation effect, supporting further investigation of positive affect, interpersonal connection and empathy as potential contributors to MDMA-assisted therapy.
Key Findings
Mystical-type experiences do occur with MDMA-assisted therapy, but they were generally not the dominant experience. The study found higher MEQ30 scores with standard-dose MDMA than with active placebo. A subset of participants experienced what the study classified as a complete mystical experience, so it would be incorrect to say MDMA does not produce mystical experiences.
The overall mystical-experience score did not significantly mediate the improvement in PTSD symptoms. This is the central finding. In other words, the data did not support the hypothesis that a stronger overall mystical experience was the mechanism explaining the therapeutic effect of MDMA-AT.
Positive Mood was the exception. Of the MEQ30 dimensions examined, the Positive Mood component showed a significant mediation effect. This suggests that the positive emotional experience associated with MDMA may be more relevant to therapeutic change than the broader mystical-experience construct.
The authors therefore point towards MDMA's prosocial/entactogenic effects as an area for further investigation. They specifically discuss qualities such as connection with self and others and empathy, and recommend that future studies measure these more directly. Importantly, this is a hypothesis generated by the findings, not proof that connectedness causes the PTSD improvement.
Abstract
Background:
The potential safety and efficacy of the psychedelic 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) for post-traumatic stress disorder (PTSD) has been researched in phase 2 and phase 3 clinical trials. We examined the occurrence and role of mystical experiences in MDMA-AT.
Methods:
Data were sourced from two phase 2 randomized trials of MDMA-AT for chronic PTSD, in which participants received two sessions with either MDMA or active placebo, in conjunction with psychotherapy. The Mystical Experience Questionnaire 30-item version (MEQ30) was administered after each MDMA session. The association of mystical experiences and PTSD symptom severity (Clinician Administered PTSD Scale for DSM-IV (CAPS-IV)) was analyzed using multilevel regression and mediation analyses.
Results:
Fifty-three participants with chronic PTSD were included. Standard doses of MDMA (n = 39) were associated with significantly higher mean MEQ30 scores (M = 63.1, SE = 4.9; 42.1% of maximum) compared to active placebo (M = 24.7, SE = 5.5; 16.4%), t-test p < 0.001. Mediation analysis revealed a significant indirect effect of the MEQ30 Positive Mood subscale on symptom reduction (b = –0.170, 95% CI (–0.353, –0.007)), while the MEQ total score and other subscales showed smaller, non-significant indirect effects on CAPS-IV scores.
Conclusions:
MEQ30 scores were significantly higher for MDMA sessions than for active placebo sessions in patients undergoing MDMA-assisted therapy for chronic PTSD. Among mystical-type experiences, the positive mood subscale, rather than full mystical-type states, appeared to contribute most to the mitigation of PTSD symptoms. These findings should be interpreted with caution due to the limited sample size and secondary nature of the analysis.
Bostoen TPL, Krediet E, van Schagen AM, van der Wee NJA, Giltay EJ. The occurrence and potential role of mystical experiences in MDMA-assisted therapy for PTSD: A secondary analysis. Journal of Psychopharmacology. 2026;0(0). Read Paper
For more psychedelic news and research, visit the psychedelic health professional network homepage.
